Literature DB >> 35599265

A computationally affordable approach for accurate prediction of the binding affinity of JAK2 inhibitors.

Nguyen Thi Mai1,2, Ngo Thi Lan2,3, Thien Y Vu4, Nguyen Thanh Tung5,6, Huong Thi Thu Phung7.   

Abstract

Janus kinase 2 (JAK2) inhibitors are potential anticancer drugs in the treatment of lymphoma, leukemia, thrombocytosis and particularly myeloproliferative diseases. However, the resemblance among JAK family members has challenged the identification of highly selective inhibitors for JAK2 to reduce undesired side effects. As a result, a robust search for promising JAK2 inhibitors using a computational approach that can effectively nominate new potential candidates to be further analyzed through laborious experimental operations has become necessary. In this study, the binding affinities of JAK2 inhibitors were rapidly and precisely estimated using the fast pulling of ligand (FPL) simulations combined with a modified linear interaction energy (LIE) method. The approach correlates with the experimental binding affinities of JAK2 inhibitors with a correlation coefficient of R = 0.82 and a root-mean-square error of 0.67 kcal•mol-1. The data reveal that the FPL/LIE method is highly approximate in anticipating the relative binding free energies of known JAK2 inhibitors with an affordable consumption of computational resources, and thus, it is very promising to be applied in in silico screening for new potential JAK2 inhibitors from a large number of molecules available.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fast pulling of ligand; JAK2 inhibitor; Linear interaction energy; Molecular dynamics; Relative binding affinity

Mesh:

Substances:

Year:  2022        PMID: 35599265     DOI: 10.1007/s00894-022-05149-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  53 in total

Review 1.  The linear interaction energy method for predicting ligand binding free energies.

Authors:  J Aqvist; J Marelius
Journal:  Comb Chem High Throughput Screen       Date:  2001-12       Impact factor: 1.339

2.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models.

Authors:  B Kuhn; P A Kollman
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

Review 3.  Ligand binding affinities from MD simulations.

Authors:  Johan Aqvist; Victor B Luzhkov; Bjørn O Brandsdal
Journal:  Acc Chem Res       Date:  2002-06       Impact factor: 22.384

4.  Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context.

Authors:  Nadine Homeyer; Friederike Stoll; Alexander Hillisch; Holger Gohlke
Journal:  J Chem Theory Comput       Date:  2014-06-24       Impact factor: 6.006

Review 5.  Computational methods for biomolecular docking.

Authors:  T Lengauer; M Rarey
Journal:  Curr Opin Struct Biol       Date:  1996-06       Impact factor: 6.809

Review 6.  Software for molecular docking: a review.

Authors:  Nataraj S Pagadala; Khajamohiddin Syed; Jack Tuszynski
Journal:  Biophys Rev       Date:  2017-01-16

Review 7.  Computer-aided drug design.

Authors:  G R Marshall
Journal:  Annu Rev Pharmacol Toxicol       Date:  1987       Impact factor: 13.820

8.  Computer-Aided Drug Design Methods.

Authors:  Wenbo Yu; Alexander D MacKerell
Journal:  Methods Mol Biol       Date:  2017

9.  Oversampling Free Energy Perturbation Simulation in Determination of the Ligand-Binding Free Energy.

Authors:  Son Tung Ngo; Trung Hai Nguyen; Nguyen Thanh Tung; Pham Cam Nam; Khanh B Vu; Van V Vu
Journal:  J Comput Chem       Date:  2019-12-16       Impact factor: 3.376

Review 10.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities.

Authors:  Samuel Genheden; Ulf Ryde
Journal:  Expert Opin Drug Discov       Date:  2015-04-02       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.